Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNB-001 in angina patients with moderate chronic kidney disease undergoing PCI
2007-002208-17Phase 2Active
- Sponsor
- Danube Pharmaceuticals
- Start
- Aug 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in angina pectoris and chronic kidney disease (CKD) comparing DNB-001 with Placebo (2 arms). Primary endpoints: Change in serum creatinine from baseline to peak post-PCI and Change in cardiac troponin I from baseline to peak post-PCI. Started Aug 2007; status: active.
02
Drugs
DNB-001
03
Conditions
angina pectorischronic kidney disease (CKD)
Beyond the preview
Go deeper on 2007-002208-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002208-17.